National Graphite Corp. 是一家探勘公司,從事黃金、白銀及相關礦物的探勘。公司總部位於北萊茵-西發利亞州杜塞爾多夫。該公司於2009年6月30日上市。公司正致力於開發一種名為elafin的候選藥物,用於治療術後發炎併發症。Elafin是一種人類同源蛋白質。公司在德國運營,與臨床階段公司合作,開發用於治療各種疾病、罕見疾病以及醫療需求未獲滿足之疾病的新型生物實體或新型治療平台。Biotech Development Corp. 是該公司的子公司。截至2015年2月28日,公司尚未產生任何收入。
NGRC stock price ended at $0.04 on 星期二, after rising 33.33%
On the latest trading day May 19, 2026, the stock price of NGRC rose by 33.33%, climbing from $0.04 to $0.04. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.04 and a high of $0.04. Notably, trading volume dropped by 7.2K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 8.2K shares were traded, equating to a market value of approximately $6.1M.